Figure 1A



vehicle
anti-EGFR GlycoMab
28H1 IgG-IL2 qm
28H1 IgG-IL2 qm + anti-EGFR GlycoMab
Survival %
100
80
60
40
20
0
0
10
20
30
40
50
60
70
Experiment day

Figure 1B



vehicle
anti-EGFR GlycoMab
DP47GS IgG-IL2 qm
DP47GS IgG-IL2 qm + anti-EGFR GlycoMab
Survival %
100
80
60
40
20
0
0
10
20
30
40
50
60
70
Experiment day

Figure 2A



% total killing
0
10
20
30
40
50
60
0
0.01
0.1
1
10
100
anti-EGFR GlycoMab concentration (ng/ml)
untreated
0.57 nM Proleukin
0.57 nM 28H1 IgG-IL2 qm

Figure 2B



% total killing
0
10
20
30
40
50
60
0
0.01
0.1
1
10
100
anti-EGFR GlycoMab concenration (ng/ml)
untreated
5.7 nM Proleukin
5.7 nM 28H1 IgG-IL2 qm

Figure 3A



CH1A1A IgG-IL-2 qm
anti-EGFR GlycoMab
vehicle
CH1A1A IgG-IL-2 qm + anti-EGFR GlycoMab
survival %
100
90
80
70
60
50
40
30
20
10
0
1
21
41
61
81
101
121
141
161
181
201
221
241
experiment day

Figure 3B



vehicle
CH1A1A IgG-IL-2 qm + cetuximab
CH1A1A IgG-IL-2 qm
cetuximab
survival %
100
90
80
70
60
50
40
30
20
10
0
1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97
experiment day

Figure 4A



vehicle
anti-EGFR GlycoMab
CH1A1A IgG-IL-2 qm
CH1A1A IgG-IL-2 qm + anti-EGFR GlycoMab
survival %
100
80
60
40
20
0
0
20
40
60
80
100
120
140
160
180
200
220
240
experiment day

Figure 4B



vehicle
CH1A1A IgG-IL-2 qm + cetuximab
CH1A1A IgG-IL-2 qm
cetuximab
survival %
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
experiment day

Figure 5




vehicle
CH1A1A IgG-IL-2 qm + anti-Her3 GlycoMab
CH1A1A IgG-IL-2 qm
anti-Her3 GlycoMab
survival %
100
90
80
70
60
50
40
30
20
10
0
1
5
9
13
17
21
25
29
33
37
41
45
experiment day

Figure 6


anti-EGFR GlycoMab
28H1 IgG-IL-2 qm + anti-EGFR GlycoMab
anti-EGFR GlycoMab + Proleukin®
vehicle
survival %
100
80
60
40
20
0
0
20
40
60
80
100
120
140
160
180
200
220
240
260
experiment day



% killing
50
40
30
20
10
0
untreated
Her3 1000 ng/ml
Her3 100 ng/ml
Her3 10 ng/ml
% killing
0.01
0.1
1
10
100
1000
CH1A1A IgG-IL-2 qm (nM)
untreated
Her3 1000 ng/ml
Her3 100 ng/ml
Her3 10 ng/ml

Figure 7



% CD25+ NK cells
100
80
60
40
20
0
untreated
1000 ng/ml Her3
100 ng/ml Her3
10 ng/ml Her3
% CD25+ NK cells
0.01
0.1
1
10
100
1000
CEA-IL2v (nM)
untreated
1000 ng/ml Her3
100 ng/ml Her3
10 ng/ml Her3

Figure 8A



% CD69+ NK cells
100
80
60
40
20
0
untreated
1000 ng/ml Her3
100 ng/ml Her3
10 ng/ml Her3
% CD69+ NK cells
0.01
0.1
1
10
100
1000
CEA-IL2v (nM)
untreated
Her3 1000 ng/ml
Her3 100 ng/ml
Her3 10 ng/ml

Figure 8B